Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiner Wiest

Showing results (61-70 of 117) with videos related to

Pageof 12
Sort By:
The American Journal of Gastroenterology|April 22, 2008
Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind studyMichael Schepke, Reiner Wiest, Sebastian Flacke, et al.
Gut Microbes|July 27, 2021
Dysbiotic microbiota interactions in Crohn's diseaseEsther Caparrós, Reiner Wiest, Michael Scharl, et al.
World Journal of Gastroenterology|April 17, 2010
Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertensionLukas Moleda, Lars Jurzik, Matthias Froh, et al.
Lipids in Health and Disease|January 19, 2021
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosisSusanne Feder, Reiner Wiest, Thomas S Weiss, et al.
Biochimica Et Biophysica Acta|April 9, 2005
Characterization of the human zinc finger protein 267 promoter: essential role of nuclear factor YKanghong Hu, Marina Fink, Matthias Froh, et al.
European Journal of Immunology|December 16, 2021
Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol-associated disease etiologyKilian Weigand, Georg Peschel, Jonathan Grimm, et al.
Cytokine|June 12, 2016
Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosisElisabeth M Meier, Rebekka Pohl, Lisa Rein-Fischboeck, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|August 22, 2009
Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertensionMarkus Resch, Reiner Wiest, Lukas Moleda, et al.
Metabolism: Clinical and Experimental|November 17, 2009
Splanchnic concentrations and postprandial release of visceral adipokinesReiner Wiest, Lukas Moleda, Stefan Farkas, et al.
Journal of Hepatology|December 6, 2005
Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertensionReiner Wiest, Lars Jurzik, Lukas Moleda, et al.
Pageof 12

Showing results (61-70 of 117) with videos related to

Sort By:
Pageof 12
The American Journal of Gastroenterology|April 22, 2008
Irbesartan plus low-dose propranolol versus low-dose propranolol alone in cirrhosis: a placebo-controlled, double-blind studyMichael Schepke, Reiner Wiest, Sebastian Flacke, et al.
Gut Microbes|July 27, 2021
Dysbiotic microbiota interactions in Crohn's diseaseEsther Caparrós, Reiner Wiest, Michael Scharl, et al.
World Journal of Gastroenterology|April 17, 2010
Role of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertensionLukas Moleda, Lars Jurzik, Matthias Froh, et al.
Lipids in Health and Disease|January 19, 2021
Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels are not associated with severity of liver disease and are inversely related to cholesterol in a cohort of thirty eight patients with liver cirrhosisSusanne Feder, Reiner Wiest, Thomas S Weiss, et al.
Biochimica Et Biophysica Acta|April 9, 2005
Characterization of the human zinc finger protein 267 promoter: essential role of nuclear factor YKanghong Hu, Marina Fink, Matthias Froh, et al.
European Journal of Immunology|December 16, 2021
Soluble CD137 is a novel serum marker of liver cirrhosis in patients with hepatitis C and alcohol-associated disease etiologyKilian Weigand, Georg Peschel, Jonathan Grimm, et al.
Cytokine|June 12, 2016
Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosisElisabeth M Meier, Rebekka Pohl, Lisa Rein-Fischboeck, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|August 22, 2009
Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertensionMarkus Resch, Reiner Wiest, Lukas Moleda, et al.
Metabolism: Clinical and Experimental|November 17, 2009
Splanchnic concentrations and postprandial release of visceral adipokinesReiner Wiest, Lukas Moleda, Stefan Farkas, et al.
Journal of Hepatology|December 6, 2005
Enhanced Y1-receptor-mediated vasoconstrictive action of neuropeptide Y (NPY) in superior mesenteric arteries in portal hypertensionReiner Wiest, Lars Jurzik, Lukas Moleda, et al.
Pageof 12